New medicine to treat chronic graft-versus-host disease

View source ↗

Summary

The European Medicines Agency has approved Rezurock (belumosudil) for adults with chronic graft-versus-host disease after failure or intolerance to at least one…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• REZUROCK (belumosudil)

Snippet

Rezurock addresses unmet need when other treatments are unsuccessful or unsuitable